Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP) announced its participation in two investor conferences in February and March 2022. The first event is BioCom California's 12th Annual Global Life Science Partnering Conference, taking place from February 22-24, where Pierre Kyme will present on February 23 at 3:30 PM PT. The second event is the 2nd Annual Chardan Microbiome Medicines Summit on March 1, featuring Brian Varnum at 10:00 AM ET. Armata specializes in bacteriophage therapeutics targeting antibiotic-resistant infections.

MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in two upcoming investor conferences.

Details can be found below:

BioCom California's 12th Annual Global Life Science Partnering Conference (February 22-24, 2022)
Location: Format:	The Lodge at Torrey Pines, San Diego, California Corporate Presentation
Date:	Wednesday, February 23, 2022
Time:	3:30 PM – 3:45 PM PT
Presenter:	Pierre Kyme, Vice President Corporate Development
2nd Annual Chardan Microbiome Medicines Summit (March 1, 2022)
Format: Date:	Virtual Corporate Presentation Tuesday, March 1, 2022
Time:	10:00 AM ET
Presenter:	Brian Varnum, Chief Executive Officer

To register for the Chardan event, please use the following link: Chardan Metagenomics and Microbiome Medicines Summit

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.

Media Contacts:
At Armata:
Steve Martin
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
858-800-2492

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-301484564.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Armata Pharmaceuticals participating in the BioCom California Conference?

Armata Pharmaceuticals is participating in the BioCom California's 12th Annual Global Life Science Partnering Conference from February 22-24, 2022.

What is the date and time of Armata's presentation at the BioCom Conference?

Armata's presentation at the BioCom Conference is scheduled for February 23, 2022, from 3:30 PM to 3:45 PM PT.

Who will present for Armata Pharmaceuticals at the BioCom Conference?

Pierre Kyme, Vice President of Corporate Development, will present for Armata Pharmaceuticals at the BioCom Conference.

When will Armata Pharmaceuticals present at the Chardan Microbiome Medicines Summit?

Armata Pharmaceuticals will present at the 2nd Annual Chardan Microbiome Medicines Summit on March 1, 2022.

What time is Armata's presentation at the Chardan Summit?

Armata's presentation at the Chardan Microbiome Medicines Summit is set for 10:00 AM ET.

Who is presenting for Armata Pharmaceuticals at the Chardan Summit?

Brian Varnum, Chief Executive Officer, will present for Armata Pharmaceuticals at the Chardan Summit.